# US 2023/0272415 A1 · Genetic modification of cytokine inducible sh2-containing protein (cish) gene

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0272415 A1
- Document ID: US20230272415A1
- Status: Published application
- Kind: A1
- Application number: 17/992,704
- Filed: 2022-11-22
- Published: 2023-08-31
- Earliest claimed: 2017-11-09
- Assignees: Sangamo Therapeutics, Inc.
- Applicants: Sangamo Therapeutics, Inc.
- Inventors: Anthony Conway; Gary K. Lee
- Web page: https://patentgrep.com/patent/US20230272415A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 15/85: for animal cells
- C12N 9/224: {Class 1 CAS enzyme complex, e.g. multi-enzyme}
- C12N 15/90: Stable introduction of foreign DNA into chromosome
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 2319/81: containing a Zn-finger domain for DNA binding
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure is in the field of genome engineering, particularly targeted genetic modification of a CISH gene.

## Claims

### Claim at position 1

-10. (canceled)

### Claim 11

A zinc finger protein comprising 6 zinc finger domains each comprising a recognition helix region, wherein the zinc finger protein comprises the recognition helix regions of the proteins designated F1-F6 in the order F1 to F6, and wherein the recognition helix region comprises the proteins:
F1 (SEQ ID NO: 2), F2 (SEQ ID NO: 3), F3 (SEQ ID NO: 4), F4 (SEQ ID NO: 5), F5 (SEQ ID NO: 6), and F6 (SEQ ID NO: 7);
F1 (SEQ ID NO: 8), F2 (SEQ ID NO: 9), F3 (SEQ ID NO: 10), F4 (SEQ ID NO: 11), F5 (SEQ ID NO: 9), and F6 (SEQ ID NO: 12);
F1 (SEQ ID NO: 13), F2 (SEQ ID NO: 14), F3 (SEQ ID NO: 10), F4 (SEQ ID NO: 15), F5 (SEQ ID NO: 16), and F6 (SEQ ID NO: 17);
F1 (SEQ ID NO: 18), F2 (SEQ ID NO: 19), F3 (SEQ ID NO: 20), F4 (SEQ ID NO: 21), F5 (SEQ ID NO: 18), and F6 (SEQ ID NO: 22);
F1 (SEQ ID NO: 23), F2 (SEQ ID NO: 24), F3 (SEQ ID NO: 25), F4 (SEQ ID NO: 26), F5 (SEQ ID NO: 27), and F6 (SEQ ID NO: 28);
F1 (SEQ ID NO: 29), F2 (SEQ ID NO: 30), F3 (SEQ ID NO: 16), F4 (SEQ ID NO: 31), F5 (SEQ ID NO: 32), and F6 (SEQ ID NO: 33);
F1 (SEQ ID NO: 34), F2 (SEQ ID NO: 35), F3 (SEQ ID NO: 32), F4 (SEQ ID NO: 36), F5 (SEQ ID NO: 37), and F6 (SEQ ID NO: 38); or
F1 (SEQ ID NO: 27), F2 (SEQ ID NO: 28), F3 (SEQ ID NO: 25), F4 (SEQ ID NO: 39), F5 (SEQ ID NO: 32), and F6 (SEQ ID NO: 12).

### Claim 12 (depends on 11)

A fusion protein comprising the zinc finger protein of claim 11 and a wild-type or engineered cleavage domain or wild-type or engineered cleavage half-domain.

### Claim 13 (depends on 11)

A polynucleotide encoding one or more proteins of claim 11.

### Claim 14 (depends on 12)

An isolated cell comprising one or more proteins of claim 12.

### Claim 15 (depends on 14)

The isolated cell of claim 14 or a cell descended therefrom, wherein the cell is selected from the group consisting of a T effector cell, a T regulatory cell and a hematopoietic stem cell.

### Claim 16 (depends on 11)

A kit comprising the protein of claim 11.

### Claim at position 8

-19. (canceled)

### Claim 20 (depends on 11)

A pharmaceutical composition comprising a zinc finger protein of claim 11.

### Claim 21 (depends on 13)

A pharmaceutical composition comprising a polynucleotide of claim 13.

### Claim 22 (depends on 14)

A pharmaceutical composition comprising an isolated cell of claim 14.

### Claim 23

A method of integrating a donor polynucleotide into an endogenous CISH gene comprising:
(a) contacting one or more cells with a zinc finger nuclease to cleave the endogenous CISH gene, wherein the zinc finger nuclease comprises six zinc finger domains, wherein each zinc finger domain comprises a recognition helix region designated F1-F6 in the order F1 to F6, and wherein the recognition helix region comprises the proteins:
F1 (SEQ ID NO: 2), F2 (SEQ ID NO: 3), F3 (SEQ ID NO: 4), F4 (SEQ ID NO: 5), F5 (SEQ ID NO: 6), and F6 (SEQ ID NO: 7);
F1 (SEQ ID NO: 8), F2 (SEQ ID NO: 9), F3 (SEQ ID NO: 10), F4 (SEQ ID NO: 11), F5 (SEQ ID NO: 9), and F6 (SEQ ID NO: 12);
F1 (SEQ ID NO: 13), F2 (SEQ ID NO: 14), F3 (SEQ ID NO: 10), F4 (SEQ ID NO: 15), F5 (SEQ ID NO: 16), and F6 (SEQ ID NO: 17);
F1 (SEQ ID NO: 18), F2 (SEQ ID NO: 19), F3 (SEQ ID NO: 20), F4 (SEQ ID NO: 21), F5 (SEQ ID NO: 18), and F6 (SEQ ID NO: 22);
F1 (SEQ ID NO: 23), F2 (SEQ ID NO: 24), F3 (SEQ ID NO: 25), F4 (SEQ ID NO: 26), F5 (SEQ ID NO: 27), and F6 (SEQ ID NO: 28);
F1 (SEQ ID NO: 29), F2 (SEQ ID NO: 30), F3 (SEQ ID NO: 16), F4 (SEQ ID NO: 31), F5 (SEQ ID NO: 32), and F6 (SEQ ID NO: 33);
F1 (SEQ ID NO: 34), F2 (SEQ ID NO: 35), F3 (SEQ ID NO: 32), F4 (SEQ ID NO: 36), F5 (SEQ ID NO: 37), and F6 (SEQ ID NO: 38); or
F1 (SEQ ID NO: 27), F2 (SEQ ID NO: 28), F3 (SEQ ID NO: 25), F4 (SEQ ID NO: 39), F5 (SEQ ID NO: 32), and F6 (SEQ ID NO: 12); and
(b) introducing a donor polynucleotide into the one or more cells, such that the donor polynucleotide is integrated into the cleaved endogenous CISH gene.

### Claim 24 (depends on 23)

The method of claim 23, wherein the donor polynucleotide comprises a polynucleotide sequence encoding a Chimeric Antigen Receptor (CAR), an engineered or endogenous T cell receptor (TCR), an antibody-coupled T cell receptor (ACTR), or any combination thereof.
